2025 Q4 -tulosraportti
UUTTA
5 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
34,55%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 791 | - | - | ||
| 960 | - | - | ||
| 935 | - | - | ||
| 967 | - | - | ||
| 4 401 | - | - |
Ylin
3,082VWAP
Alin
2,922VaihtoMäärä
2,5 824 215
VWAP
Ylin
3,082Alin
2,922VaihtoMäärä
2,5 824 215
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenWell, maybe a buy again… Alden has less than a day's turnover left etc
·3 päivää sitten · MuokattuI have followed this chat in recent weeks after ABG gave the stock a price target of 4.5 kroner. And from what I have read, I got the impression that many here were convinced that ABG had underestimated the upside and that it was now just a matter of buying with both hands. The price increase testified to the market's broad optimism. My gut feeling said something else, and Q4 revealed that it was a wise decision. I refrained from buying awaiting hard facts. There are many here who believe in Nykode, and that's probably good if one thinks the money will yield returns very far into the future. But the hyping here, which has led to many losing their savings, is an ethical question that I think hypesters should reflect on. Yes, everyone is responsible for their purchases, but what people say matters. I look forward to a more informed chat than rockets, champagne glasses and noise. That was all.
2 päivää sitten2 päivää sittenJust the way the chair of the board and the ceo have been appointed, I find it hard to believe that nykode isn’t set up for big things moving forward. I can understand why short term investors who looked at the information presented in the report may see differently than I do, there is an omission of what to expect going forward after March and cash burn has increased. But, for me, March is more important than the last financial report. Unless there’s someone who has found information that I haven’t found, I see the past few days decline as a bit of an over reaction.16 t sitten16 t sittenJust to say, the presentation in March is a risk, it’s pretty much binary as to what happens to the value of the company as a result of what is presented, it isn’t just about ocr it’s about extended quality life of the patients, what I want to hear in the presentation is something about the average extended life of the patients is still being determined, something along those lines at least, There may be a reason why nykode hasn’t set a plan beyond March, and it may not be negative, it could equally be keeping the ball in their court, if big pharma wants involvement then they may have their own path forward and nykode giving their time plan now may dissuade potential deals. this last part has come from generative ai, so take that as you please, the prompt given is as such to not allow “cheer leading” like those models gravitate towards. Looking forward to the presentation, I’m not too bothered about a dip in the prices before we get anything concrete, l’m not a day trader, I have faith in the long term here. I have a high tolerance for risk. Let’s keep the forum grown up and respectful :)
·3 päivää sittenThe trading pattern in recent days strongly resembles brutal shorting. We will monitor the shareholder lists over the next two days to see if there is another reason.·3 päivää sittenWe will see this afternoon if short passes 0.5%.
3 päivää sitten3 päivää sittenAs we all probably know : In cancer immunotherapy: • 10–20% = average • 20–30% = good • 30–40% = very good ✅ • 40%+ = potential breakthrough 38.5% = close to the level Big Pharma considers valuable
·3 päivää sittenMerck & Co's patent on Keytruda expires in 2028. The fact that Nykode's mix shows such good results makes the giant Merck & Co perhaps pay extra close attention? Also note Merck & Co's strategy of splitting off its «human health» business. When Nykode is valued at 1x equity, the entire Nykode is very cheap for the really big and smart guys!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
5 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
34,55%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenWell, maybe a buy again… Alden has less than a day's turnover left etc
- ·3 päivää sitten · MuokattuI have followed this chat in recent weeks after ABG gave the stock a price target of 4.5 kroner. And from what I have read, I got the impression that many here were convinced that ABG had underestimated the upside and that it was now just a matter of buying with both hands. The price increase testified to the market's broad optimism. My gut feeling said something else, and Q4 revealed that it was a wise decision. I refrained from buying awaiting hard facts. There are many here who believe in Nykode, and that's probably good if one thinks the money will yield returns very far into the future. But the hyping here, which has led to many losing their savings, is an ethical question that I think hypesters should reflect on. Yes, everyone is responsible for their purchases, but what people say matters. I look forward to a more informed chat than rockets, champagne glasses and noise. That was all.2 päivää sitten2 päivää sittenJust the way the chair of the board and the ceo have been appointed, I find it hard to believe that nykode isn’t set up for big things moving forward. I can understand why short term investors who looked at the information presented in the report may see differently than I do, there is an omission of what to expect going forward after March and cash burn has increased. But, for me, March is more important than the last financial report. Unless there’s someone who has found information that I haven’t found, I see the past few days decline as a bit of an over reaction.16 t sitten16 t sittenJust to say, the presentation in March is a risk, it’s pretty much binary as to what happens to the value of the company as a result of what is presented, it isn’t just about ocr it’s about extended quality life of the patients, what I want to hear in the presentation is something about the average extended life of the patients is still being determined, something along those lines at least, There may be a reason why nykode hasn’t set a plan beyond March, and it may not be negative, it could equally be keeping the ball in their court, if big pharma wants involvement then they may have their own path forward and nykode giving their time plan now may dissuade potential deals. this last part has come from generative ai, so take that as you please, the prompt given is as such to not allow “cheer leading” like those models gravitate towards. Looking forward to the presentation, I’m not too bothered about a dip in the prices before we get anything concrete, l’m not a day trader, I have faith in the long term here. I have a high tolerance for risk. Let’s keep the forum grown up and respectful :)
- ·3 päivää sittenThe trading pattern in recent days strongly resembles brutal shorting. We will monitor the shareholder lists over the next two days to see if there is another reason.·3 päivää sittenWe will see this afternoon if short passes 0.5%.
- 3 päivää sitten3 päivää sittenAs we all probably know : In cancer immunotherapy: • 10–20% = average • 20–30% = good • 30–40% = very good ✅ • 40%+ = potential breakthrough 38.5% = close to the level Big Pharma considers valuable·3 päivää sittenMerck & Co's patent on Keytruda expires in 2028. The fact that Nykode's mix shows such good results makes the giant Merck & Co perhaps pay extra close attention? Also note Merck & Co's strategy of splitting off its «human health» business. When Nykode is valued at 1x equity, the entire Nykode is very cheap for the really big and smart guys!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 791 | - | - | ||
| 960 | - | - | ||
| 935 | - | - | ||
| 967 | - | - | ||
| 4 401 | - | - |
Ylin
3,082VWAP
Alin
2,922VaihtoMäärä
2,5 824 215
VWAP
Ylin
3,082Alin
2,922VaihtoMäärä
2,5 824 215
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
2025 Q4 -tulosraportti
UUTTA
5 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
1,00 NOK/osake
Viimeisin osinko
34,55%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenWell, maybe a buy again… Alden has less than a day's turnover left etc
- ·3 päivää sitten · MuokattuI have followed this chat in recent weeks after ABG gave the stock a price target of 4.5 kroner. And from what I have read, I got the impression that many here were convinced that ABG had underestimated the upside and that it was now just a matter of buying with both hands. The price increase testified to the market's broad optimism. My gut feeling said something else, and Q4 revealed that it was a wise decision. I refrained from buying awaiting hard facts. There are many here who believe in Nykode, and that's probably good if one thinks the money will yield returns very far into the future. But the hyping here, which has led to many losing their savings, is an ethical question that I think hypesters should reflect on. Yes, everyone is responsible for their purchases, but what people say matters. I look forward to a more informed chat than rockets, champagne glasses and noise. That was all.2 päivää sitten2 päivää sittenJust the way the chair of the board and the ceo have been appointed, I find it hard to believe that nykode isn’t set up for big things moving forward. I can understand why short term investors who looked at the information presented in the report may see differently than I do, there is an omission of what to expect going forward after March and cash burn has increased. But, for me, March is more important than the last financial report. Unless there’s someone who has found information that I haven’t found, I see the past few days decline as a bit of an over reaction.16 t sitten16 t sittenJust to say, the presentation in March is a risk, it’s pretty much binary as to what happens to the value of the company as a result of what is presented, it isn’t just about ocr it’s about extended quality life of the patients, what I want to hear in the presentation is something about the average extended life of the patients is still being determined, something along those lines at least, There may be a reason why nykode hasn’t set a plan beyond March, and it may not be negative, it could equally be keeping the ball in their court, if big pharma wants involvement then they may have their own path forward and nykode giving their time plan now may dissuade potential deals. this last part has come from generative ai, so take that as you please, the prompt given is as such to not allow “cheer leading” like those models gravitate towards. Looking forward to the presentation, I’m not too bothered about a dip in the prices before we get anything concrete, l’m not a day trader, I have faith in the long term here. I have a high tolerance for risk. Let’s keep the forum grown up and respectful :)
- ·3 päivää sittenThe trading pattern in recent days strongly resembles brutal shorting. We will monitor the shareholder lists over the next two days to see if there is another reason.·3 päivää sittenWe will see this afternoon if short passes 0.5%.
- 3 päivää sitten3 päivää sittenAs we all probably know : In cancer immunotherapy: • 10–20% = average • 20–30% = good • 30–40% = very good ✅ • 40%+ = potential breakthrough 38.5% = close to the level Big Pharma considers valuable·3 päivää sittenMerck & Co's patent on Keytruda expires in 2028. The fact that Nykode's mix shows such good results makes the giant Merck & Co perhaps pay extra close attention? Also note Merck & Co's strategy of splitting off its «human health» business. When Nykode is valued at 1x equity, the entire Nykode is very cheap for the really big and smart guys!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 791 | - | - | ||
| 960 | - | - | ||
| 935 | - | - | ||
| 967 | - | - | ||
| 4 401 | - | - |
Ylin
3,082VWAP
Alin
2,922VaihtoMäärä
2,5 824 215
VWAP
Ylin
3,082Alin
2,922VaihtoMäärä
2,5 824 215
Välittäjätilasto
Dataa ei löytynyt